조선일보

Celltrion extends Remsima surge past 1 trillion won with Europe, SC gains

Celltrion's autoimmune disease treatment Remsima (ingredient infliximab) topped 1 trillion won in annual sales again this year. Celltrion said on the 10th that Remsima posted about 1.0495 trillion won ...
Business Wire

Celltrion Finalizes Clinical Trials for Remsima SC, Planning to File a Marketing Authorization Application to the EMA in H2

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion, Inc. (KRX:068270) today announced that the company has completed Phase 3 clinical trial for ‘Remsima SC’, the subcutaneous (SC) version of Remsima®, ...
조선일보

Celltrion launches liquid Remsima in Europe, wins Nordic tenders and targets growth

Celltrion said on the 11th that it has launched the liquid formulation of its autoimmune disease treatment Remsima (ingredient name Infliximab) in Europe. According to Celltrion, the company recently ...
Business Wire

Celltrion Healthcare receives EU marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima SC™, for the treatment of people with rheumatoid ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that the European Commission has approved Remsima SC ™ (CT-P13 SC, biosimilar infliximab) for patients with RA. 1 Remsima SC ...